Lack of cross-reactivity between cefotaxime and imipenem

K. Aouam1, F. Ben Romdhaneb, C. Loussiaf, M. Chakovab, N. A. Boughattas, N. Bouzouaia

1 Service de Pharmacologie, Faculté de Médecine, Monastir, Tunisia
b Service de Maladies Infectieuses, Hôpital Fattouma Bourguiba, Monastir, Tunisia

Introduction

Cephalosporins and carbapenems are structurally related, since they share the same β-lactam ring and are potentially able to induce hypersensitivity reactions [1]. Cross-reactivity between imipenem and cephalosporins has not been described. We report the case of a patient who developed an allergic skin reaction to cefotaxime and subsequently tolerated imipenem.

Case report

An 18-year-old tetraplegic male was admitted in the Infectious Diseases Department for urinary tract infection (UTI). After urinary sampling for cytobacteriological examination, empirical antibiotic therapy with cefotaxime 1 g IV and gentamicin 80 mg IM was started. Three hours later the patient developed an erythematous maculopapular and pruritic rash over almost the entire body. Neither oedema nor dyspnoea was present. A pruritic rash followed. Laboratory examination performed 2 days after cefotaxime withdrawal and the absence of other medication to which it might be attributable. Like cephalosporins, carbapenems belong to the β-lactam antibiotic group but are reserved for the treatment of severe infections by highly resistant organisms [2]. Cefotaxime and imipenem are structurally related, since they share the same β-lactam ring and would be expected to have a similar propensity to cause hypersensitivity reactions [3]. Unlike that between penicillins and cephalosporins [4], and vice versa [5], cross-reactivity between cephalosporins and carbapenems had not been described in the literature. This case demonstrates the safe use of imipenem in a patient with a history of cefotaxime allergy. Since our patient tolerated imipenem even though exhibiting an allergic reaction to cefotaxime, it can be argued that sensitisation was not to the β-lactam ring but to one of the side chains included in the chemical structure of cefotaxime. While we are naturally not recommending systematic prescription of imipenem in patients allergic to cephalosporins, we show that if clinical circumstances require it, it is possible to try imipenem in patients who exhibit allergic reactions to cefotaxime. As far as we are aware this is the first case to demonstrate the lack of reactivity to imipenem in a patient with a known allergy to cefotaxime.

Discussion

Our case presents a patient allergic to cefotaxime who tolerated treatment with imipenem. We believe that the allergic rash was related to cefotaxime, for the following reasons: the temporal relationship between the start of cefotaxime therapy and the cutaneous eruption, the resolution of the skin lesion after cefotaxime withdrawal and the absence of other medication to which it might be attributable. Like cephalosporins, carbapenems belong to the β-lactam antibiotic group but are reserved for the treatment of severe infections by highly resistant organisms [2]. Cefotaxime and imipenem are structurally related, since they share the same β-lactam ring and would be expected to have a similar propensity to cause hypersensitivity reactions [3]. Unlike that between penicillins and cephalosporins [4], and vice versa [5], cross-reactivity between cephalosporins and carbapenems had not been described in the literature. This case demonstrates the safe use of imipenem in a patient with a history of cefotaxime allergy. Since our patient tolerated imipenem even though exhibiting an allergic reaction to cefotaxime, it can be argued that sensitisation was not to the β-lactam ring but to one of the side chains included in the chemical structure of cefotaxime. While we are naturally not recommending systematic prescription of imipenem in patients allergic to cephalosporins, we show that if clinical circumstances require it, it is possible to try imipenem in patients who exhibit allergic reactions to cefotaxime. As far as we are aware this is the first case to demonstrate the lack of reactivity to imipenem in a patient with a known allergy to cefotaxime.

Acknowledgements

The authors are greatly indebted to Professor Mahmoud Bchir for his help in improving the language of this article.

Correspondence:
Dr K. Aouam
Laboratoire de Pharmacologie
Faculté de Médecine de Monastir
Rue Avicenne
5019 Monastir
Tunisia
E-Mail: aouam_k@yahoo.fr

References

The many reasons why you should choose SMW to publish your research

**What Swiss Medical Weekly has to offer:**

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

**Editorial Board**

Prof. Jean-Michel Dayer, Geneva  
Prof. Peter Gehr, Berne  
Prof. André P. Perruchoud, Basel  
Prof. Andreas Schaffner, Zurich  
( Editor in chief)  
Prof. Werner Straub, Berne  
Prof. Ludwig von Segesser, Lausanne

**International Advisory Committee**

Prof. K. E. Juhani Airaksinen, Turku, Finland  
Prof. Anthony Bayes de Luna, Barcelona, Spain  
Prof. Hubert E. Blum, Freiburg, Germany  
Prof. Walter E. Haefeli, Heidelberg, Germany  
Prof. Nino Kuenzli, Los Angeles, USA  
Prof. René Lutter, Amsterdam, The Netherlands  
Prof. Claude Martin, Marseille, France  
Prof. Josef Patsch, Innsbruck, Austria  
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:
http://www.smw.ch/set_authors.html

**Impact factor Swiss Medical Weekly**

All manuscripts should be sent in electronic form, to:

EMH Swiss Medical Publishers Ltd.  
SMW Editorial Secretariat  
Farnburgerstrasse 8  
CH-4132 Muttenz

Manuscripts: submission@smw.ch  
Letters to the editor: letters@smw.ch  
Editorial Board: red@smw.ch  
Internet: http://www.smw.ch